Findings from this trial reinforce the preclinical data supporting the approval of the LP.8.1-adapted COVID-19 vaccine for the 2025-2026 season. Topline results were announced from a phase 3 trial ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

More than five years since Covid-19 was declared a pandemic, we’re still facing the regular emergence of new variants of the virus, SARS-CoV-2. The latest variant on the rise is LP.8.1. It’s ...

COVID rarely rates a mention in the news these days, yet it hasn't gone away. SARS-CoV-2, the virus that causes COVID, is still with us. It continues to infect thousands of Australians each month, ...

Get the Well Enough newsletter with Harry Bullmore for tips on living a healthier, happier and longer life Get the Well Enough email with Harry Bullmore More than five years since COVID was declared a ...

Add Yahoo as a preferred source to see more of our stories on Google. -Credit:Reach Publishing Services Limited A new Covid variant, known as LP. 8.1, is on the rise, causing thousands of infections ...

Moderna’s LP.8.1-adapted COVID-19 vaccine has been recommended by the European Medicines Agency (EMA)’s human medicines committee. The Committee for Medicinal Products for Human Use (CHMP) has ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

According to the latest UK Health Security Agency (UKHSA) data, nearly a third of England's coronavirus cases are attributed to a specific variant, with people aged 80 and above being ...

Almost a third of Covid cases in England are linked to a specific variant, with people aged 80 and over most affected. The most recent data from the UK Health Security Agency (UKHSA), shows that ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...